title: EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.
abstract: The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.
authors: Thoracic Surgery and Lung Transplantation Unit, Foundation IRCCS (Scientific Institute for Research Hospitalization and Health Care) "Ca' Granda" General Hospital, University of Milan, Milan, Italy.
authors: Alberto
authors: A
authors: Antonicelli
authors: Stefano
authors: S
authors: Cafarotti
authors: Alice
authors: A
authors: Indini
authors: Alessio
authors: A
authors: Galli
authors: Andrea
authors: A
authors: Russo
authors: Alfredo
authors: A
authors: Cesario
authors: Filippo Maria
authors: FM
authors: Lococo
authors: Patrizia
authors: P
authors: Russo
authors: Alberto Franco
authors: AF
authors: Mainini
authors: Luca Giuseppe
authors: LG
authors: Bonifati
authors: Mario
authors: M
authors: Nosotti
authors: Luigi
authors: L
authors: Santambrogio
authors: Stefano
authors: S
authors: Margaritora
authors: Pierluigi Maria
authors: PM
authors: Granone
authors: André Emanuel
authors: AE
authors: Dutly
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR targeted therapy; NSCLC; TKIs; advanced; mutation; resistance.